| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kN,kN']bis(tetradecanoato-kO)platinum monohydrate manufacturers
|
| | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kN,kN']bis(tetradecanoato-kO)platinum monohydrate Basic information |
| | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kN,kN']bis(tetradecanoato-kO)platinum monohydrate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | 25℃: DMSO | | form | Powder |
| | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kN,kN']bis(tetradecanoato-kO)platinum monohydrate Usage And Synthesis |
| Uses | Miriplatin hydrate (SM-11355 hydrate) is a chemotherapy agent which belongs to the class of alkylating agents. | | Biological Activity | Miriplatin hydrate (SM-11355 hydrate) is an effective chemotherapeutic agent and is a kind of alkylator. | | in vitro | Miriplatin suspended in lipiodol (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis. | | in vivo | Miriplatin (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces the growth of tumor in rats bearing AH109A cells. | | References | [1] Kishimoto S, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000 Mar;23(3):344-8. DOI:10.1248/bpb.23.344
[2] Hanada M, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009 Aug;64(3):473-83. DOI:10.1007/s00280-008-0895-3 |
| | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kN,kN']bis(tetradecanoato-kO)platinum monohydrate Preparation Products And Raw materials |
|